Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 13/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 3/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7901774 | 1.00 | FOLH1 (0.43) | FOLH1SMN1; SMN2TGM2ALBSIRT2 | |
| SCHEMBL7911993 | 0.91 | FOLH1 (0.45) | FOLH1SMN1; SMN2TGM2ALB | |
| SCHEMBL7912005 | 0.91 | FOLH1 (0.45) | FOLH1SMN1; SMN2TGM2ALB | |
| SCHEMBL7909235 | 0.88 | FOLH1 (0.43) | FOLH1SMN1; SMN2 | |
| SCHEMBL7911902 | 0.88 | FOLH1 (0.40) | FOLH1SMN1; SMN2TGM2ALBSIRT2 | |
| SCHEMBL7911894 | 0.88 | FOLH1 (0.40) | FOLH1SMN1; SMN2TGM2ALBSIRT2 | |
| SCHEMBL7909229 | 0.88 | FOLH1 (0.43) | FOLH1SMN1; SMN2 | |
| SCHEMBL8711067 | 0.88 | FOLH1 (0.42) | FOLH1SMN1; SMN2TGM2ALB | |
| SCHEMBL7908742 | 0.83 | FOLH1 (0.41) | FOLH1TGM2SIRT2SIRT1 | |
| SCHEMBL7908736 | 0.83 | FOLH1 (0.41) | FOLH1TGM2SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6207708-B1 | FOR THERAPY AND PROPHYLAXIS OF AUTOIMMUNE AND/OR INFLAMMATORY CONDITIONS AFFECTING THE JOINTS SUCH AS ARTHRITIS, AND INFLAMMATORY BOWEL DISEASE, CARDIVASCULAR ISCHEMIA, DIABETES, CONGESTIVE HEART FAILURE, MYOCARDITIS, ATHEROSCLEROSIS, | G. D. SEARLE & COMPANY | 2001-03-27 | — | — | US | claimed |
| EP-0885188-B1 | HYDROXYAMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | SEARLE & CO (US) | 2000-09-27 | — | — | EP | claimed |
| EP-0885188-A1 | HYDROXYAMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-12-23 | — | — | EP | claimed |
| WO-1997032844-A9 | HYDROXYAMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | — | 1997-12-24 | — | — | WO | claimed |
| WO-1997032844-A1 | HYDROXYAMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1997-09-12 | — | — | WO | claimed |
| US-6576780-B1 | Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors | GD SEARLE & COMPANY | 2003-06-10 | — | — | US | disclosed |
| US-6207708-B1 | FOR THERAPY AND PROPHYLAXIS OF AUTOIMMUNE AND/OR INFLAMMATORY CONDITIONS AFFECTING THE JOINTS SUCH AS ARTHRITIS, AND INFLAMMATORY BOWEL DISEASE, CARDIVASCULAR ISCHEMIA, DIABETES, CONGESTIVE HEART FAILURE, MYOCARDITIS, ATHEROSCLEROSIS, | G. D. SEARLE & COMPANY | 2001-03-27 | — | — | US | disclosed |
| EP-0885188-B1 | HYDROXYAMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | SEARLE & CO (US) | 2000-09-27 | — | — | EP | disclosed |
| WO-1997032844-A9 | HYDROXYAMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | — | 1997-12-24 | — | — | WO | disclosed |